Assignee
OSE IMMUNOTHERAPEUTICS
FR·24 granted patents·34 pending applications·23 citations·filing 2014–2025
Top patents by PatentIndex Score
58 records- 0187US11279766B2Anti-SIRPa antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Mar 22, 2022·3 cites·47 claims
- 0284US2025051446A1Anti-CD28 Humanized Antibodies Formulated for Administration to HumansOSE IMMUNOTHERAPEUTICS·Filed 2023·Application pending·0 cites
- 0383US2024294659A1Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious DiseasesOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 0482US11191820B2Method for inducing early T memory response with short peptides anti-tumor vaccineOSE IMMUNOTHERAPEUTICS·Filed 2015·Granted Dec 7, 2021·2 cites·15 claims
- 0582US10364287B2Anti-CD28 humanized antibodiesOSE IMMUNOTHERAPEUTICS·Filed 2016·Granted Jul 30, 2019·3 cites·14 claims
- 0681US11352430B2Humanized anti-human-PD-1 antibody and its use in cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2019·Granted Jun 7, 2022·2 cites·15 claims
- 0781US10428152B2Antibodies directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2015·Granted Oct 1, 2019·3 cites·11 claims
- 0881US2024279352A1Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancerOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 0980US12371502B2Antibodies directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jul 29, 2025·0 cites·21 claims
- 1080US11440964B2Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibodyOSE IMMUNOTHERAPEUTICS·Filed 2019·Granted Sep 13, 2022·2 cites·17 claims
- 1180US11230602B2Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Jan 25, 2022·2 cites·28 claims
- 1279US2024352135A1Antibodies and polypeptides directed against cd127OSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 1378US11325959B2Method for manufacturing a stable emulsion for peptide deliveryOSE IMMUNOTHERAPEUTICS·Filed 2018·Granted May 10, 2022·2 cites·11 claims
- 1478US11098128B2Antibodies and polypeptides directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Aug 24, 2021·1 cites·26 claims
- 1577US2024384349A1Biomarkers for assessing the response status for treatment of inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patientsOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 1676US12252546B2Anti-SIRPa antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Mar 18, 2025·0 cites·23 claims
- 1776US10434157B2Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasisOSE IMMUNOTHERAPEUTICS·Filed 2014·Granted Oct 8, 2019·3 cites·11 claims
- 1875US2022411510A1Anti-CD28 Humanized Antibodies Formulated for Administration to HumansOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 1974US2025215108A1ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONSOSE IMMUNOTHERAPEUTICS·Filed 2025·Application pending·0 cites
- 2072US11926671B2Antibodies and polypeptides directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2021·Granted Mar 12, 2024·0 cites·17 claims
- 2172US2022281993A1Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious DiseasesOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2271US2022298259A1Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancerOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2370US12331118B2Humanized anti-human-PD-1 antibody and methods of using them for cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jun 17, 2025·0 cites·9 claims
- 2470US2024400698A1Anti-chemokin like receptor 1 antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 2569US12331115B2Uses of anti-SIRPg antibodiesOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jun 17, 2025·0 cites·3 claims
- 2669US2020115453A1Anti-CD28 Humanized Antibodies Formulated for Administration to HumansOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 2767US2018215824A1Anti-CD28 Humanized Antibodies Formulated for Administration to HumansOSE IMMUNOTHERAPEUTICS·Filed 2018·Application pending·0 cites
- 2865US2025297324A1Biomarkers of IL7R Modulator ActivityOSE IMMUNOTHERAPEUTICS·Filed 2023·Application pending·0 cites
- 2964US11981713B2Method for manufacturing a stable emulsion for peptide deliveryOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted May 14, 2024·0 cites·18 claims
- 3063US2025250354A1New class of molecules for selective clearance of antibodyOSE IMMUNOTHERAPEUTICS·Filed 2023·Application pending·0 cites
- 3162US2026035434A1Heterodimeric fc-clec-1 fusion molecule and uses thereofOSE IMMUNOTHERAPEUTICS·Filed 2023·Application pending·0 cites
- 3261US2026049141A1Multifunctional molecule directed against cd28OSE IMMUNOTHERAPEUTICS·Filed 2023·Application pending·0 cites
- 3361US2025340632A1SPECIFIC ANTAGONIST ANTI-SIRPg ANTIBODIESOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 3460US12077820B2Biomarkers for assessing the response status for treatment of Inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patientsOSE IMMUNOTHERAPEUTICS·Filed 2018·Granted Sep 3, 2024·0 cites·9 claims
- 3557US2025026839A1Identification of CLEC-1 Ligand and Uses ThereofOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 3657US2023227565A1Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 AgentOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 3755US12448454B2Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereofOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Oct 21, 2025·0 cites·18 claims
- 3855US2024182571A1New scaffold for bifunctional molecules with improved propertiesOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 3955US2024182572A1Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domainsOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 4054US2018312600A1Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancerOSE IMMUNOTHERAPEUTICS·Filed 2016·Application pending·0 cites
- 4154US2024067727A1Bifunctional anti-pd1/il-7 moleculesOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
- 4252US2021147558A1Anti-chemokin like receptor 1 antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 4351US11713356B2Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancerOSE IMMUNOTHERAPEUTICS·Filed 2018·Granted Aug 1, 2023·0 cites·34 claims
- 4450US2022056135A1Bifunctional anti-pd-1/sirpa moleculeOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 4550US2023181721A1Vaccine against sars-cov virusOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
- 4650US2023331852A1Anti-clec-1a antibodies and antigen-binding fragment thereofOSE IMMUNOTHERAPEUTICS·Filed 2020·Application pending·0 cites
- 4749US12534533B2Anti-chemokine like receptor 1 humanized antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2020·Granted Jan 27, 2026·0 cites·20 claims
- 4849US2022389104A1Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 AgentOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
- 4949US2023303648A1Bifunctional molecules comprising an il-7 variantOSE IMMUNOTHERAPEUTICS·Filed 2020·Application pending·0 cites
- 5048US11696936B2Treatment of cancerOSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Jul 11, 2023·0 cites·17 claims
Showing the top 50 of 58 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →